U.S. markets open in 2 hours 23 minutes
  • S&P Futures

    3,774.25
    -15.25 (-0.40%)
     
  • Dow Futures

    30,664.00
    -117.00 (-0.38%)
     
  • Nasdaq Futures

    11,468.00
    -61.50 (-0.53%)
     
  • Russell 2000 Futures

    1,700.30
    -7.70 (-0.45%)
     
  • Crude Oil

    108.10
    +2.34 (+2.21%)
     
  • Gold

    1,790.00
    -17.30 (-0.96%)
     
  • Silver

    19.64
    -0.71 (-3.50%)
     
  • EUR/USD

    1.0456
    -0.0027 (-0.26%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.70
    +0.54 (+1.92%)
     
  • GBP/USD

    1.2056
    -0.0119 (-0.98%)
     
  • USD/JPY

    135.2880
    -0.4400 (-0.32%)
     
  • BTC-USD

    19,087.05
    +19.89 (+0.10%)
     
  • CMC Crypto 200

    410.62
    -20.85 (-4.83%)
     
  • FTSE 100

    7,159.77
    -9.51 (-0.13%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Those who invested in Antares Pharma (NASDAQ:ATRS) five years ago are up 44%

·2 min read

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Antares Pharma, Inc. (NASDAQ:ATRS) share price is up 44% in the last five years, that's less than the market return. The last year hasn't been great either, with the stock up just 4.0%.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

View our latest analysis for Antares Pharma

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During the last half decade, Antares Pharma became profitable. That would generally be considered a positive, so we'd expect the share price to be up.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

It is of course excellent to see how Antares Pharma has grown profits over the years, but the future is more important for shareholders. This free interactive report on Antares Pharma's balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Antares Pharma provided a TSR of 4.0% over the last twelve months. Unfortunately this falls short of the market return. If we look back over five years, the returns are even better, coming in at 8% per year for five years. Maybe the share price is just taking a breather while the business executes on its growth strategy. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should learn about the 2 warning signs we've spotted with Antares Pharma (including 1 which is a bit unpleasant) .

We will like Antares Pharma better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.